Cargando…
Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
Systems biology studies have demonstrated that different (epi)genetic and pathophysiological alterations may be mapped onto a single tumor’s clinical phenotype thereby revealing commonalities shared by cancers with divergent phenotypes. The success of this approach in cancer based on analyses of tra...
Autores principales: | Hampel, Harald, Goetzl, Edward J., Kapogiannis, Dimitrios, Lista, Simone, Vergallo, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450260/ https://www.ncbi.nlm.nih.gov/pubmed/30984002 http://dx.doi.org/10.3389/fphar.2019.00310 |
Ejemplares similares
-
Biomarkers for Alzheimer’s Disease (AD) and the Application of Precision Medicine
por: Lukiw, Walter J., et al.
Publicado: (2020) -
microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
por: Zhao, Yuhai, et al.
Publicado: (2020) -
Mitochondrial Electron Transport Chain Protein Abnormalities Detected in Plasma Extracellular Vesicles in Alzheimer’s Disease
por: Yao, Pamela J., et al.
Publicado: (2021) -
Long-COVID: Phase 2 of the COVID-19 Pandemic
por: Goetzl, Edward J., et al.
Publicado: (2022) -
Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19
por: Goetzl, Edward J., et al.
Publicado: (2023)